European approval of isatuximab (Sarclisa) for treatment of adults with relapsed multiple myeloma

The approval, in combination with carfilzomib and dexamethasone, is based on data from the Phase III IKEMA study (n=302) which showed improved progression-free survival (median not reached vs 19.15 months with carfilzomib and dexamethasone).

Source:

PharmaTimes